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Angiogenesis is critical for the growth and metastasis of endometrial cancer and is therefore an important therapeutic target. Vascular
endothelial growth factor-A (VEGF-A) is a key molecule in angiogenesis, but the identification of related molecules and the
angiopoietins suggests a more complex picture. We investigated the presence of transcripts for VEGF-A, VEGF-B, VEGF-C, VEGF-D,
Angiopoietin-1 and Angiopoietin-2 in benign endometrium, atypical complex hyperplasia (ACH) and endometrioid endometrial
carcinoma using in situ hybridisation. We confirmed the presence of VEGF-A mRNA in the epithelial cells of cancers examined (13
out of 13), but not in benign endometrium or ACH. We also demonstrate, using quantitative polymerase chain reaction, that levels of
VEGF-B mRNA are significantly lower in endometrial cancer than benign endometrium. We conclude that loss of VEGF-B may
contribute to the development of endometrial carcinoma by modulating availability of receptors for VEGF-A.
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Angiogenesis is a critical event in the growth and spread of
tumours (Folkman, 1990). The vascular endothelial growth factor
family (VEGFs) and the angiopoietins are key factors in this
process (Fong et al, 1995; Shalaby et al, 1995; Ferrara et al, 1996;
Maisonpierre et al, 1997; Thurston et al, 1999). Vascular
endothelial growth factor-A is a dimeric glycoprotein existing as
four main isoforms by alternative splicing from a single gene. The
coding regions of the VEGF gene comprise eight exons. The first
four are conserved but alternative splicing of the last four gives rise
to mRNAs of 121, 145, 165, 189 and 206 amino acids, respectively
(VEGF121, VEGF145, VEGF165, VEGF189, VEGF206) (Houck et al,
1991; Tischer et al, 1991; Charnock-Jones et al, 1993). The VEGF-A
isoforms bind the tyrosine kinase receptors VEGFR-1 (flt-1) and
VEGFR-2 (KDR/flk-1) to promote endothelial cell proliferation,
migration and increased vascular permeability. Elevated levels of
VEGF-A are found in many tumours including cancers of the
endometrium (Doldi et al, 1996; Fujimoto et al, 1998) and ovarian
epithelium (Olson et al, 1994; Boocock et al, 1995; Abu-Jawdeh
et al, 1996). When VEGF-A signalling is blocked with VEGF-
neutralising antibodies (Olson et al, 1996) or dominant-negative
receptors (Millauer et al, 1994), tumour angiogenesis and growth
are impaired.
However, the family of VEGF genes has expanded with the
discovery of other VEGFs, for example, VEGF-B (Olofsson et al,
1996a), VEGF-C (Joukov et al, 1996) and VEGF-D (Achen et al,
1998), which share significant sequence homology with VEGF-A.
VEGF-B exists as two splice variants, a heparin binding isoform of
167 amino acids (VEGF-B167) and a secreted isoform of 186 amino
acids (VEGF-B186) (Olofsson et al, 1996b). Whereas VEGF-A binds
to both the VEGFR-1 and VEGFR-2 receptors, VEGF-B binds only
to the VEGFR-1 receptor (flt-1) (Olofsson et al, 1998). Vascular
endothelial growth factor-B forms homodimers and can hetero-
dimerise with VEGF-A (Olofsson et al, 1996a) to promote
endothelial cell proliferation in vitro (Olofsson et al, 1996a).
Both VEGF-C and VEGF-D are ligands for VEGFR-2 (KDR) and
the third VEGF receptor VEGFR-3 (flt-4) (Joukov et al, 1996;
Achen et al, 1998). VEGFR-3 is expressed by adult lymphatic
endothelial cells but not by adult vascular endothelium. There is a
strong association between lymphovascular density and VEGF-C
expression in human malignant mesothelioma, suggesting this
pathway as an important therapeutic target (Ohta et al, 1999).
A second family of growth factors, the angiopoietins, are ligands
for the tyrosine kinase receptor Tie-2 (Davis et al, 1996;
Maisonpierre et al, 1997). The two ligands share 60% sequence
homology and bind with equal affinity to Tie-2. Angiopoietin-1
(Ang-1) maintains pericyte/endothelial cell interactions (Hanahan,
1997; Thurston et al, 1999) while Angiopoietin-2 (Ang-2) is a
functional antagonist of Ang-1 and leads to marked vessel
regression in tumours in the absence of VEGF-A (Holash et al,
1999). Compared to Ang-1, which is widely expressed in adult
tissues, Ang-2 is selectively expressed at sites of active angiogen-
esis, for example, the corpus luteum of the ovary (Goede et al,
1998) and endometrium (Li et al, 2001).
Angiogenesis is an important feature of endometrial cancer as
microvessel density is an independent prognostic indicator of both
progression and overall survival (Kaku et al, 1997). Furthermore,
there is a progressive increase in microvessel density from benign
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yendometrium through the cancer precursor, atypical complex
hyperplasia (ACH) to invasive disease (Abulafia et al, 1995).
While VEGF-A mRNA and protein are present in endometrial
cancer (Doldi et al, 1996; Guidi et al, 1996; Fujimoto et al, 1998), its
expression in ACH is unknown. Vascular endothelial growth
factor-C (Hirai et al, 2001) and VEGF-D (Yokoyama et al, 2003)
have both been correlated with a poor prognosis in endometrial
cancer, but the expression of VEGF-B has not been described. In
order to further investigate a possible role for other angiogenic
factors in endometrial cancer, we investigated the presence of
transcripts for VEGF-A, VEGF-B, VEGF-C, VEGF-D, Ang-1 and
Ang-2 in benign postmenopausal endometrium, ACH and
endometrioid endometrial carcinoma by in situ hybridisation
and used quantitative polymerase chain reaction (PCR) to




A total of 13 carcinoma specimens were examined using in situ
hybridisation. All were endometrioid-type carcinomas. Five benign
postmenopausal endometrial specimens and five complex atypical
hyperplasias were also examined for comparison. The age range of
the patients was 51–87 years (median 57 years). Histopathological
findings and clinical data are shown in Table 1. Presence or
absence of lymphovascular space involvement is indicated, where
reported, in the table. The survival status for each patient was
noted at the time of preparation of this manuscript. Ethical
committee approval was obtained from the committee of
Addenbrookes Hospital NHS Trust.
Tissue samples
In situ hybridisation and immunohistochemistry were performed
on formalin-fixed, paraffin-embedded endometrial tissue. Tissue
used for reverse transcription–PCR (RT–PCR) and quantitative
PCR was snap-frozen from endometrium removed during
endometrial curettage or total hysterectomy, after examination
by a histopathologist.
Production of radiolabelled riboprobes for in situ
hybridisation
Antisense and sense (control) RNA probes were generated against
VEGF-A, VEGF-B, VEGF-C, VEGF-D, angiopoietin-1 and angio-
poietin-2 (Sowter et al, 1997). For VEGF-A, probes were designed
to span the first four exons thus detecting the four commonly
occurring isoforms. The sequences were amplified in pCRscript SK
(Stratagene Ltd., Cambridge, UK) and pBluescript II KS vectors
(Stratagene Ltd., Cambridge, UK). Radioactive, single-stranded
probes incorporating
33P-UTP (Amersham International plc, Little
Chalfont, Buckinghamshire, UK) were carried out with 1mg
plasmid template using the Ambion MAXIscript transcription kit
(Ambion Inc., Austin, TX, USA) before phenol extraction and
ethanol precipitation.
Identification of mRNA encoding VEGF-A, VEGF-B,
VEGF-C, VEGF-D, angiopoietin-1 and angiopoietin-2 by
in situ hybridisation
Tissue sections (6mm) were cut onto slides coated with 3-
aminopropyltriethoxy-silane (Sigma Chemical, Poole, Dorset,
UK). The hybridisation procedure was performed as described
by Clark et al (1996). The riboprobe was incubated with the tissue
sections for 18h at 551C. The sections were washed and treated
with RNAse A (Sigma Chemicals, St Louis, USA), before being
coated with autoradiographic emulsion (Amersham Pharmacia
Biotech UK Ltd, Aylesbury, UK) and exposed for 21 days at 41C.
Sections were developed with photographic developer (Kodak
D19) and counterstained with Mayer’s haemalum (BDH Chemicals,
Lutterworth, UK) before viewing.
Immunohistochemistry for cytokeratin and CD-68
Immunohistochemistry was performed on serial sections to
identify the cell types expressing the transcripts. Mouse antibodies
to human cytokeratin (clone MNF116; Dako, Ltd., High Wycombe,
Table 1 Clinical and histopathological details for patient samples used in the study
Patient Histology Age Status FIGO stage Grade LVS involved Tamoxifen use
1 Benign 51 Alive — — — N
2 Benign 57 Alive — — — N
3 Benign 80 Alive — — — N
4 Benign 63 Alive — — — N
5 Benign 68 Alive — — — N
6 ACH 56 Alive — — — N
7 ACH 58 Alive — — — N
8 ACH 52 Alive — — — N
9 ACH 69 Alive — — — N
10 ACH 52 Alive — — — N
11 Endometrioid cancer 41 Alive 1C 1 N N
12 Endometrioid cancer 56 Alive 2B 2 N/R N
13 Endometrioid cancer 48 Alive 2B 2 Y N
14 Endometrioid cancer 46 Alive 1B 2 N N
15 Endometrioid cancer 71 Alive 3A 3 N/R N
16 Endometrioid cancer 87 Alive 1B 3 N N
17 Endometrioid cancer 54 Alive 1B 3 N Y
18 Endometrioid cancer 78 Deceased 1C 3 N N
19 Endometrioid cancer 84 Deceased 4A 3 Y N
20 Endometrioid cancer 56 Alive 3B 3 N/R N
21 Endometrioid cancer 52 Alive 1B 3 N/R Y
22 Endometrioid cancer 68 Deceased 4A 3 Y Y
23 Endometrioid cancer 81 Alive 1B 3 Y N
ACH¼atypical complex hyperplasia; LVS¼lymphovascular space involvement N/R¼not reported N¼never, Y¼yes.
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yBuckinghamshire, UK) and human CD68, a macrophage marker,
(clone PG-1; Dako, Ltd.) were used as described previously (Clark
et al, 1996). Mouse IgG (Dako, Ltd.) incubated with serial sections
provided negative controls.
Reverse transcription–PCR
RNA from benign postmenopausal endometrium, ACH and
endometrioid endometrial carcinoma was analysed by RT–PCR
to determine whether mRNA for VEGF-C was present (Figure 1).
Total RNA was extracted from snap-frozen tissue using acid
phenol purification (Chomczynski and Sacchi, 1987). Samples for
PCR were unrelated to those used for in situ hybridisation. RNA
was annealed with oligo-dT primers (Pharmacia Biotech LTD., St
Albans, UK) and cDNA was synthesised using reverse transcriptase
(HT Biotechnology LTD., Cambridge, UK). Polymerase chain
reaction for VEGF-C was performed using the upstream primer 50-
TGCCGATGCATGTCTAAACT-30, and the downstream reverse
complement primer 5’-TGAACAGGTCTCTTCATCCAGC-30 for 40
cycles (15s at 951C and 60s at 601C).
Quantitative PCR
RNA was extracted and purified and cDNA was prepared as above.
Quantitative, real-time PCR was performed in triplicate using the
ABI PRISM 7700 Sequence Detector (Applied Biosystems, War-
rington, UK) according to the manufacturer’s instructions and the
resultant data were averaged. Non-template controls were included
in each experiment. Specific oligonucleotide primers and probes
were designed for VEGF-B using Primer Express
s 1.5 software
(Applied Biosystems, Warrington, UK). Specific primers and probe
for Ang-2 were a gift from Mrs K Day of The Reproductive
Molecular Research Group at the University of Cambridge
Department of Obstetrics and Gynaecology. Details for VEGF-B




A1 ml volume of each cDNA was amplified using PCR Master
Mix (Applied Biosystems, Warrington, UK) under the following
PCR conditions: 501C for 2min, 951C for 10min, followed by 40
cycles of 951C for 15s and 601C for 1min. b-Actin and 18s RNA
were used as endogenous control sequences for VEGF-B and
Angiopoietin-2, respectively. Preliminary experiments confirmed
that the endogenous control sequences were amplified at the same
rate as the target sequences (data not shown). The threshold cycle
(CT) was determined for each sample. CT value is the cycle number
at which the level of reporter fluorescence rises above a preset
threshold level. Normalisation was achieved by subtracting the
mean CT value for each endogenous control triplicate from the
mean CT value for each target gene triplicate. Target gene
abundance was calculated for each tissue type.
Statistical analyses
The presence or absence of specific in situ hybridisation for each
transcript was compared across the different histological cate-
gories using the two-tailed Fisher’s exact probability test. This was
computed using the R statistical computing programme (www.r-
project.org). Statistical significance was accepted as Po0.05. For
results of quantitative PCR, normalised log-transformed transcript
levels were compared between groups using the unpaired Student’s
t-test (two-tailed).
RESULTS
Expression of members of the VEGF family and
angiopoietins by in situ hybridisation
The presence of VEGF-A was detected in all cases of endometrioid
endometrial cancer (Table 2 and Figure 2) and was increased near
areas of necrosis. Hybridisation for VEGF-A was not seen in cases
of ACH or in sections of benign postmenopausal endometrium.
In contrast, hybridisation of the VEGF-B riboprobe was seen in
all the five cases of ACH (Table 2 and Figure 2). There was
continued expression for VEGF-B in low-grade tumours that
diminished as the grade of the tumour increased. Vascular
endothelial growth factor-B mRNA was also present in epithelial
and stromal compartments (Figure 2), although, unlike VEGF-A,
there was no apparent increase in hybridisation near areas of
necrosis.
Messenger RNA encoding VEGF-C was not detected in any of
the tissues examined using in situ hybridisation (Table 2 and
Figure 1). A specimen of human lymphoma was used as a positive
control and demonstrated specific hybridisation (Figure 2).
However, PCR amplification of VEGF-C cDNA was seen in all
the samples of endometrial cancer (13 out of 13) and ACH (three
out of three) examined (Figure 1), in addition to six out of 7 benign
postmenopausal endometria. These findings confirm the presence
of VEGF-C in benign, premalignant and malignant endometrium
(Hirai et al, 2001), although at levels beneath the detection
threshold for in situ hybridisation.
Messenger RNA encoding VEGF-D was present in three of the
five ACH specimens and in six of the 13 carcinomas (one
moderately differentiated tumour and five poorly differentiated
tumours). The distribution of silver grains did not correspond with
epithelial tumour cells but did co-localise with tumour-associated
macrophages (CD-68 positive cells) in serial sections (Figure 3).
Hybridisation for Ang-1 mRNA was seen in only one benign and
one ACH specimen. Similarly, mRNA encoding Ang-2 was seen in
no benign tissues and in only one of the five hyperplastic samples.
In contrast, while hybridisation was absent in well/moderately
differentiated cancers, hybridisation for Ang-2 mRNA was clearly
demonstrated in four out of nine of the poorly differentiated
tumours examined. Hybridisation was most marked in macro-
phage-rich regions of these tumours and was seen to correspond
with tumour-associated macrophages (CD-68) upon immunostain-
ing of serial sections (Figure 3). In all of the experiments described,
there was no specific hybridisation when the sense probes were
used on adjacent sections.
Transcript abundance of VEGF-B and Ang-2 in benign
endometrium and endometrial carcinoma assessed by
quantitative PCR
Real-time, quantitative PCR was carried out using cDNA generated
from benign postmenopausal endometria and endometrioid-type
endometrial adenocarcinoma. The abundance of VEGF-B tran-
script was greater in benign endometrium (n¼7) than in atypical
hyperplasia (n¼3) (P¼0.13) and endometrial cancer (n¼17)
(P¼0.04) (Figure 4A). Conversely, cDNA encoding Ang-2 was
246 bp
 l   r   c  A  B   C D   E  F  G  H  I   J       K  L M  N  O   P Q  R  S  T U  V  W
Figure 1 Reverse transcription PCR analysis of VEGF-C in samples of
benign endometrium (A–G), ACH (H–J) and endometrioid endometrial
carcinoma. Well differentiated carcinoma (K–M), moderately differentiated
carcinoma (N–S) and poorly differentiated carcinoma (T–W). Lane r
represents an RNA control in which the RT step was omitted and lane c
represents a negative control in which the cDNA was replaced by water.
The size of the transcripts (shown on the right of the figure) was estimated
by co-electrophoresis of a 1kb ladder (lane l).
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yFigure 2 Expression of mRNA encoding VEGF-related factors in the epithelial cells of endometrioid endometrial carcinoma and ACH. In situ hybridisation
with VEGF-A antisense probe in a moderately differentiated (FIGO grade 2) carcinoma shown under dark-field (A) and light-field (C) conditions shows
hybridisation in epithelial carcinoma cells. There is no specific hybridisation when a sense probe (negative control) is used (B). The scale bar in (B) applies to (A),
(B), (E), (F), (I)a n d( J). Immunostaining of a serial section with anti-human cytokeratin confirms the epithelial localisation of silver grains (D) (scale bar applies to
ACH (C)a n d( D). In situ hybridisation with VEGF-B antisense probe in ACH shown under dark-field (E) and light-field (G) conditions shows diffuse hybridisation
in epithelial and stromal cells. There is no specific hybridisation when a sense probe (negative control) is used (F). Immunostaining with anti-human cytokeratin
(H) identifies the epithelial and stromal cells (H) (scale bar applies to (G)a n d( H). In situ hybridisation with VEGF-C antisense probe in a poorly differentiated
(FIGO grade 3) carcinoma shown under dark-field conditions (I) shows no specific hybridisation when compared with a human B-cell lymphoma (J).
Angiogenesis in endometrial cancer
CM Holland et al
894





























yTable 2 Expression of VEGF-A, VEGF-B, VEGF-C, VEGF-D, Ang-1 and Ang-2 detected by in situ
hybridisation in sections of endometrium
Endometrial histology n VEGF-A VEGF-B VEGF-C VEGF-D ANG-1 ANG-2
Benign 5 0/5 0/5 0/5 0/5 1/5 0/5
ACH 5 1/5 5/5* 0/5 3/5 1/5 1/5
FIGO G1/2 carcinoma 4 4/4* 3/4 0/4 1/4 0/4 0/4
FIGO G3 carcinoma 9 9/9* 4/9 0/9 5/9 0/9 4/9
*Po0.05.
Figure 3 Expression of mRNA encoding VEGF-D and Ang-2 in macrophages infiltrating a poorly differentiated (FIGO grade 3) endometrioid endometrial
carcinoma. In situ hybridisation with VEGF-D antisense probe shown under dark-field (A) conditions and light-field conditions (C). In situ hybridisation with
VEGF-D sense (control) probe shows no specific hybridisation (B) (scale bar applies to (A), (B), (E) and (F)). Immunostaining with anti-human CD68 in a
serial section (D), localises the silver grains to tumour associated macrophages (TAMs) (scale bar applies to (C), (D), (G) and (H)). In situ hybridisation with
Ang-2 antisense probe shown under dark-field (E) and light-field (G) conditions. In situ hybridisation with Ang-2 sense (control) probe (F) shows no specific
hybridisation. Anti-human cytokeratin staining (H) localises the hybridisation to TAMs.
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ymore abundant in the cancer samples (n¼17) than in benign
postmenopausal endometrium (n¼4) (Figure 4B), although this
did not reach statistical significance (P¼0.49).
DISCUSSION
These findings confirm the expression of VEGF-A in endometrial
cancer (Doldi et al, 1996; Guidi et al, 1996; Fujimoto et al, 1998;
Fine et al, 2000), although in contrast to other published reports
(Fujimoto et al, 1998; Fine et al, 2000), we did not demonstrate
VEGF-A mRNA in benign specimens. This may be explained by
the inclusion of both pre- and postmenopausal endometrium in
other studies (Fujimoto et al, 1998). Messenger RNA for VEGF-A is
abundant in premenopausal endometrium (Charnock-Jones et al,
1993). Our findings support those of Guidi et al (1996), who
demonstrated little or no mRNA expression in benign atrophic
endometrium. We demonstrated VEGF-A mRNA in only one out
of 5 specimens of ACH compared with 13 out of 13 endometrioid
cancers. These differences may be due to necrosis within the
malignant tissue. Hypoxia, in necrotic areas of cancer, leads to the
upregulation of transcription (Tischer et al, 1991) and increased
stability of VEGF-A mRNA (Levy et al, 1996).
Messenger RNA and protein for the related growth factor VEGF-
B have previously been identified in other tumours including
ovarian carcinoma (Sowter et al, 1997). We demonstrate, using
quantitative PCR, that mRNA encoding VEGF-B is more abundant
in benign postmenopausal endometrium than in endometrial
adenocarcinoma. The results also suggest that there may be a
relative loss of VEGF-B mRNA in ACH although this was not
statistically significant and may reflect small sample numbers. We
show, using in situ hybridisation, that where present, VEGF-B
mRNA is expressed in both epithelium and stroma of ACH and
some endometrial cancers. These findings contrast with the
overexpression of VEGF-A seen in endometrial cancers (Doldi
et al, 1996; Fujimoto et al, 1998). The distribution of VEGF-B in
both epithelial and stromal compartments of atypical hyperplasia
and some cancers is similar to that observed in ovarian cancer
(Sowter et al, 1997), but in contrast to VEGF-A, hybridisation was
not increased near areas of necrosis. Vascular endothelial growth
factor-B is not upregulated by hypoxia (Silins et al, 1997) and this
may explain the differences seen here.
The function of VEGF-B is not clear. Vascular endothelial
growth factor-1 binds VEGFR-1 (flt-1) but not VEGFR-2 (KDR)
(Olofsson et al, 1998), both of which are present in peritumoral
endothelial cells of endometrial cancers (Guidi et al, 1996). Mouse
‘knockout’ experiments suggest that the VEGFR-1 plays a role in
endothelial differentiation and/or interactions between the en-
dothelium and extracellular matrix (Fong et al, 1995), whereas
signalling through VEGFR-2 leads to endothelial cell proliferation
and migration (Waltenberger et al, 1994). Vascular endothelial
growth factor-B is therefore unlikely to promote endothelial cell
proliferation or migration directly. However, VEGF-B signalling
via VEGFR-1 may participate in the organisation of endothelial–
matrix interactions as VEGF-B increases the expression of both
uPA (urokinase-type plasminogen activator) and PAI-1 (plasmi-
nogen activator inhibitor-1) in endothelial cell cultures (Olofsson
et al, 1996a). These play a role in matrix degradation and its
inhibition, respectively.
Vascular endothelial growth factor-B could contribute to the
maintenance of host–tumour responses. Vascular endothelial
growth factor-A, produced by tumour cells, inhibits the functional
maturation of immune dendritic cells from haemopoietic progeni-
tor cells (Gabrilovich et al, 1996). This effect is mediated by
binding to VEGFR-1 (Oyama et al, 1998). Therefore, loss of VEGF-
B may contribute to the escape of tumour cells from the host
immune response by making more VEGFR-1 binding sites
available for binding by VEGF-A. Vascular endothelial growth
factor-B may thus act to suppress changes that favour the
development of endometrial cancer.
We confirmed the presence of VEGF-C mRNA in endometrial
carcinoma shown by Hirai et al (2001), but did not demonstrate
this by in situ hybridisation. Intense hybridisation for VEGF-C
mRNA is seen in endometrial natural killer cells (Li et al, 2001),
hence the VEGF-C transcript may be present in non-tumour cells
that were under-represented in our endometrial tissues.
Vascular endothelial growth factor-D binds to VEGFR-2 and
VEGFR-3 (Achen et al, 1998), both of which are present in
endometrial cancer (Guidi et al, 1996). In colon cancer, VEGFR-3
is associated with inflammatory infiltrates of TAMs (White et al,
2002) although VEGF-D has not been demonstrated in TAMs
themselves. We have shown hybridisation for VEGF-D mRNA in
ACH and both well differentiated and poorly differentiated
tumours (Table 2), although not all cases in each group were
positive. Recently, positive immunostaining for VEGF-D has been
demonstrated in both epithelium and stroma of endometrial
cancers with some cases of ACH also displaying immunopositivity
(Yokoyama et al, 2003). In the latter study, 42 and 87% of stage I/II
and stage III/IV tumours, respectively, showed significant
immunostaining. These findings may reflect differences in the
degree of inflammatory infiltration between individual tumours as
well as increased expression of VEGF-D by the tumour cells. There
is a tendency to higher TAM density in microvessel-rich tumours
(Salvesen and Akslen, 1999), and our findings indicate that TAMs
may assist in promoting angiogenesis in endometrioid endometrial
carcinoma by the secretion of VEGF-D.
Angiopoietin-1 and Ang-2 are previously unreported in






































































Figure 4 Quantitative PCR for gene transcripts in benign and malignant
endometrium. Levels of gene transcript are shown normalised to an
endogenous control sequence. Transcript levels are expressed as arbitrary
units and represent the mean for each histological group. Experiments for
each sample were performed in triplicate. (A) The level of mRNA
encoding VEGF-B is generally higher in benign postmenopausal endome-
trium than in CAH (P¼0.13) and endometrial cancer (P¼0.04). (B)
mRNA encoding Ang-2 is generally present at higher levels in endometrial
cancer than in benign postmenopausal endometrium.
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ymRNA in endometrial cancers than benign endometrium, although
this did not reach statistical significance. The latter may reflect the
small numbers of samples in the benign group. Nonetheless, the
distribution of mRNA for Ang-2, assessed by in situ hybridisation,
was similar to that of VEGF-D in TAMs (Figure 3). Both Ang-2 and
VEGF-D were only seen in association with CD68-positive cells,
although CD68-positive cells, without hybridisation for either of
these factors were also present.
Angiopoietin-2 is an antagonist of Ang-1, acting through the
Tie-2 receptor and disrupting pericyte-endothelial cell interac-
tions. In the presence of VEGF-A, Ang-2 facilitates vessel sprouting
while in its absence, regression of vessel sprouts occurs
(Maisonpierre et al, 1997). However, in active tumour angiogen-
esis, a large proportion of the blood vessels lack pericytes and can
be selectively ablated by withdrawal of VEGF-A alone (Benjamin
et al, 1999). In our series, survival did not differ significantly where
hybridisation for both VEGF-A and Ang-2 was seen and this may
reflect a high proportion of immature tumour vessels lacking
pericyte coverage. Angiopoietin-2 may also alter the response of
destabilised endothelial cells to cytokines, thus modulating
angiogenesis (Laure ´n et al, 1998).
We have shown that gene transcripts for the related growth
factors, VEGF-A and VEGF-B, are differentially expressed in
benign postmenopausal endometrium and endometrioid endome-
trial cancer. The reduced expression of VEGF-B in endometrial
cancers compared with benign endometrium suggests that VEGF-B
may play a role in maintaining normal cellular interactions in
endometrium and that loss of expression could contribute to
endometrial tumorigenesis.
ACKNOWLEDGEMENTS
This work was supported by a MRC Clinical Training Fellowship,
Award number G84/5733; an MRC Programme Grant, Grant
number G9623012 and an MRC Cooperative Group Grant number
G9722567. We are grateful to Mr Robin Crawford, Mr John Latimer
and Dr Robin Moseley, Addenbrookes Hospital, Cambridge, for
assistance with tissue collection. We also acknowledge Dr Mark
Arends, Department of Pathology, University of Cambridge, for
histopathological assessment and Dr Heidi Sowter for technical
advice and support.
REFERENCES
Abu-Jawdeh GM, Faix JD, Niloff J, Tognazzi K, Manseau E, Dvorak HF,
Brown LF (1996) Strong expression of vascular permeability factor
(vascular endothelial growth factor) and its receptors in ovarian
borderline and malignant neoplasms. Lab Invest 74: 1105–1115
Abulafia O, Triest WE, Sherer DM, Hansen CC, Ghezzi F (1995)
Angiogenesis in endometrial hyperplasia and stage I endometrial
carcinoma. Obstet Gynecol 86: 479–485
Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, Alitalo K,
Stacker SA (1998) Vascular endothelial growth factor D (VEGF-D) is a
ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF
receptor 3 (Flt4). Proc Natl Acad Sci USA 95: 548–553
Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E (1999) Selective
ablation of immature blood vessels in established human tumors follows
vascular endothelial growth factor withdrawal. J Clin Invest 103: 159–165
Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ,
Wright KA, Twentyman PR, Smith SK (1995) Expression of vascular
endothelial growth factor and its receptors flt and KDR in ovarian
carcinoma. J Natl Cancer Inst 87: 506–516
Charnock-Jones DS, Sharkey AM, Rajput-Williams J, Burch D, Schofield JP,
Fountain SA, Boocock CA, Smith SK (1993) Identification and
localization of alternately spliced mRNAs for vascular endothelial growth
factor in human uterus and estrogen regulation in endometrial
carcinoma cell lines. Biol Reprod 48: 1120–1128
Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by
acid guanidinium thiocyanate–phenol–chloroform extraction. Anal
Biochem 162: 156–159
Clark DE, Smith SK, Sharkey AM, Sowter HM, Charnock-Jones DS (1996)
Hepatocyte growth factor /scatter factor and its receptor c-met:
localisation and expression in the human placenta throughout preg-
nancy. J Endocrinol 151: 459–467
Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE,
Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD (1996)
Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-
trap expression cloning. Cell 87: 1161–1169
Doldi N, Bassan M, Gulisano M, Broccoli V, Boncinelli E, Ferrari A (1996)
Vascular endothelial growth factor messenger ribonucleic acid expres-
sion in human ovarian and endometrial cancer. Gynecol Endocrinol 10:
375–382
Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O’Shea KS, Powell-
Braxton L, Hillan KJ, Moore MW (1996) Heterozygous embryonic
lethality induced by targeted inactivation of the VEGF gene. Nature 380:
439–442
Fine BA, Valente PT, Feinstein GI, Dey T (2000) VEGF, flt-1, and KDR/flk-1
as prognostic indicators in endometrial carcinoma. Gynecol Oncol 76:
33–39
Folkman J (1990) What is the evidence that tumors are angiogenesis
dependent? J Natl Cancer Inst 82: 4–6
Fong GH, Rossant J, Gertsenstein M, Breitman ML (1995) Role of the Flt-1
receptor tyrosine kinase in regulating the assembly of vascular
endothelium. Nature 376: 66–70
Fujimoto J, Ichigo S, Hirose R, Sakaguchi H, Tamaya T (1998) Expressions
of vascular endothelial growth factor (VEGF) and its mRNA in uterine
endometrial cancers. Cancer Lett 134: 15–22
Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S,
Kavanaugh D, Carbone DP (1996) Production of vascular endothelial
growth factor by human tumors inhibits the functional maturation of
dendritic cells. Nat Med 2: 1096–1103
Goede V, Schmidt T, Kimmina S, Kozian D, Augustin HG (1998) Analysis of
blood vessel maturation processes during cyclic ovarian angiogenesis.
Lab Invest 78: 1385–1394
Guidi AJ, Abu-Jawdeh G, Tognazzi K, Dvorak HF, Brown LF (1996)
Expression of vascular permeability factor (vascular endothelial
growth factor) and its receptors in endometrial carcinoma. Cancer 78:
454–460
Hanahan D (1997) Signaling vascular morphogenesis and maintenance.
Science 277: 48–50
Hirai M, Nakagawara A, Oosaki T, Hayashi Y, Hirono M, Yoshihara T
(2001) Expression of vascular endothelial growth factors (VEGF-A/
VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial
carcinoma. Gynecol Oncol 80: 181–188
Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D,
Yancopoulos GD, Wiegand SJ (1999) Vessel cooption, regression, and
growth in tumors mediated by angiopoietins and VEGF. Science 284:
1994–1998
Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW (1991) The
vascular endothelial growth factor family: identification of a fourth
molecular species and characterization of alternative splicing of RNA.
Mol Endocrinol 5: 1806–1814
Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela
O, Kalkkinen N, Alitalo K (1996) A novel vascular endothelial growth
factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2)
receptor tyrosine kinases. EMBO J 15: 1751
Kaku T, Kamura T, Kinukawa N, Kobayashi H, Sakai K, Tsuruchi N, Saito
T, Kawauchi S, Tsuneyoshi M, Nakano H (1997) Angiogenesis in
endometrial carcinoma. Cancer 80: 741–747
Lauren J, Gunji Y, Alitalo K (1998) Is angiopoietin-2 necessary for the
initiation of tumor angiogenesis? Am J Pathol 153: 1333–1339
Levy AP, Levy NS, Goldberg MA (1996) Post-transcriptional regulation of
vascular endothelial growth factor by hypoxia. J Biol Chem 271: 2746–
2753
Li XF, Charnock-Jones DS, Zhang E, Hiby S, Malik S, Day K, Licence D,
Bowen JM, Gardner L, King A, Loke YW, Smith SK (2001) Angiogenic
growth factor messenger ribonucleic acids in uterine natural killer cells.
J Clin Endocrinol Metab 86: 1823–1834
Angiogenesis in endometrial cancer
CM Holland et al
897





























yMaisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski
C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S,
Sato TN, Yancopoulos GD (1997) Angiopoietin-2, a natural
antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55–60
Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A (1994) Glioblastoma
growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature
367: 576–579
Ohta Y, Shridhar V, Bright RK, Kalemkerian GP, Du W, Carbone M,
Watanabe Y, Pass HI (1999) VEGF and VEGF type C play an important
role in angiogenesis and lymphangiogenesis in human malignant
mesothelioma tumours. Br J Cancer 81: 54–61
Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V,
Gunji Y, Jeltsch MM, Shibuya M, Alitalo K, Eriksson U (1998) Vascular
endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and
regulates plasminogen activator activity in endothelial cells. Proc Natl
Acad Sci USA 95: 11709–11714
Olofsson B, Pajusola K, Kaipainen A, von Euler G, Joukov V, Saksela O,
Orpana A, Pettersson RF, Alitalo K, Eriksson U (1996a) Vascular
endothelial growth factor B, a novel growth factor for endothelial cells.
Proc Natl Acad Sci USA 93: 2576–2581
Olofsson B, Pajusola K, von Euler G, Chilov D, Alitalo K, Eriksson U
(1996b) Genomic organization of the mouse and human genes for
vascular endothelial growth factor B (VEGF-B) and characterization of a
second splice isoform. J Biol Chem 271: 19310–19317
Olson TA, Mohanraj D, Carson LF, Ramakrishnan S (1994) Vascular
permeability factor gene expression in normal and neoplastic human
ovaries. Cancer Res 54: 276–280
Olson TA, Mohanraj D, Carson LF, Ramakrishnan S (1996) In vivo
neutralization of vascular endothelial growth factor (VEGF)/vascular
permeability factor (VPF) inhibits ovarian carcinoma-associated ascites
formation and tumor growth. Int J Oncol 8: 505–511
Oyama T, Ran S, Ishida T, Nadaf S, Kerr L, Carbone DP, Gabrilovich DI
(1998) Vascular endothelial growth factor affects dendritic cell matura-
tion through the inhibition of nuclear factor-kappa B activation in
hemopoietic progenitor cells. J Immunol 160: 1224–1232
Salvesen HB, Akslen LA (1999) Significance of tumour-associated
macrophages, vascular endothelial growth factor and thrombospondin-
1 expression for tumour angiogenesis and prognosis in endometrial
carcinomas. Int J Cancer 84: 538–543
Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML,
Schuh AC (1995) Failure of blood-island formation and vasculogenesis in
Flk-1-deficient mice. Nature 376: 62–66
Silins G, Grimmond S, Egerton M, Hayward N (1997) Analysis of the
promoter region of the human VEGF-related factor gene. Biochem
Biophys Res Commun 230: 413–418
Sowter HM, Corps AN, Evans AL, Clark DE, Charnock-Jones DS, Smith SK
(1997) Expression and localization of the vascular endothelial growth
factor family in ovarian epithelial tumors. Lab Invest 77: 607–614
Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD,
McDonald DM (1999) Leakage-resistant blood vessels in
mice transgenically overexpressing angiopoietin-1. Science 286:
2511–2514
Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC,
Abraham JA (1991) The human gene for vascular endothelial growth
factor. Multiple protein forms are encoded through alternative exon
splicing. J Biol Chem 266: 11947–11954
Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH
(1994) Different signal transduction properties of KDR and Flt1, two
receptors for vascular endothelial growth factor. J Biol Chem 269: 26988–
26995
White JD, Hewett PW, Kosuge D, McCulloch T, Enholm BC, Carmichael J,
Murray JC (2002) Vascular endothelial growth factor-D expression is an
independent prognostic marker for survival in colorectal carcinoma.
Cancer Res 62: 1669–1675
Yokoyama Y, Charnock-Jones DS, Licence D, Yanaihara A,
Hastings JM, Holland CM, Emoto M, Sakamoto T, Maruyama, H, Sato
S, Mizunuma H, Smith SK (2003) Expression of vascular endothelial
growth factor (VEGF)-D and its receptor, VEGF Receptor 3, as a
prognostic indicator in endometrial carcinoma. Clin Cancer Res
9: 1361–1369
Angiogenesis in endometrial cancer
CM Holland et al
898
British Journal of Cancer (2003) 89(5), 891–898 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y